Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 nov. 2025 03h16 HE | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition publicerar data om fördelar av tidig behandling med golexanolon vid Parkinsons sjukdom

STOCKHOLM, 17 november 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterat data som visar varaktiga fördelar av tidig behandling med...
17 nov. 2025 03h16 HE | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition publishes data on the benefits of early treatment with golexanolone in Parkinson’s disease

STOCKHOLM – November 17, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has published data in the scientific journal...
14 nov. 2025 02h00 HE | Source: Karolinska Development AB (publ)

Delårsrapport för januari – september 2025

STOCKHOLM – den 14 november 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – september 2025. Den fulla rapporten är tillgänglig på bolagets...
14 nov. 2025 02h00 HE | Source: Karolinska Development AB (publ)

Interim Report - January-September 2025

STOCKHOLM – 14 November 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-September 2025. The full report is available on the Company's website. “We...
04 nov. 2025 02h45 HE | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics får klartecken att starta den andra delen av en klinisk fas 2-studie i kronisk njursjukdom med anemi

STOCKHOLM, 4 november, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har fått regulatoriskt godkännande att inleda den andra delen av...
04 nov. 2025 02h45 HE | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia

STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the...
03 nov. 2025 05h59 HE | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag BOOST Pharma tar in Sound Bioventures i investerarsyndikatet genom en investering om 34 miljoner kronor

STOCKHOLM, SVERIGE 3 november 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget BOOST Pharma har tagit in 34 miljoner kronor, genom ett trancherat...
03 nov. 2025 05h59 HE | Source: Karolinska Development AB (publ)

Karolinska Development portfolio company BOOST Pharma adds Sound Bioventures to investor syndicate with SEK 34 million investment

Stockholm, Sweden – November 3, 2025 – Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has raised a SEK 34 million investment structured as a...
31 oct. 2025 05h55 HE | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag BOOST Pharma presenterar positiva långtidsdata för sin cellterapi mot Osteogenesis imperfecta

STOCKHOLM, 31 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget BOOST Pharma har presenterat nya långtidsdata från den kliniska fas 1/2-studien BOOSTB4...
31 oct. 2025 05h55 HE | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company BOOST Pharma presents positive long-term data for its cell-based treatment of Osteogenesis imperfecta

STOCKHOLM, SWEDEN, October 31, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented new long-term data from the BOOSTB4 phase...

Page précédente

Page suivante